文献速递糖尿病

冠心病多基因风险评分在2型糖尿病中的增量预后价值

Incremental Prognostic Value of a Coronary Heart Disease Polygenic Risk Score in Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2024-01-01

研究纳入10556例40-79岁无既往心血管住院史的2型糖尿病患者,计算10年临床心血管风险(PCE)并构建冠心病多基因风险评分(PRS),评估PRS对主要不良心血管事件(MACE)的增量预测价值。10年时共1477例MACE,校正临床风险后PRS与MACE显著相关(每增加1个标准差HR 1.69,95%CI 1.60-1.79)。PCE风险<7.5%但PRS处于最高五分位者较最低五分位者MACE风险显著升高(HR 10.69,95%CI 5.07-22.55)。将PRS加入临床风险评分显著改善风险预测,尤其在低临床风险者中。

要点

  • 在2型糖尿病无既往心血管病者中,冠心病PRS与MACE显著相关(每SD HR 1.69,95%CI 1.60-1.79)。
  • PCE风险<7.5%但PRS最高五分位者较最低五分位者MACE风险显著升高(HR 10.69,95%CI 5.07-22.55)。
  • 将PRS加入临床风险评分显著改善风险预测,尤其在低临床风险者中。

核心结论

  • 在无既往心血管病的2型糖尿病患者中,将冠心病PRS加入临床评估可改善MACE预测,尤其在低临床风险者中。

研究设计与样本

  • 评估10556例40-79岁无既往心血管住院史的2型糖尿病患者,以招募日期计算10年临床心血管风险(PCE风险)并构建冠心病PRS。
  • 主要结局为首次MACE发生时间,评估冠心病PRS对PCE风险的附加增量预测价值。

主要发现

  • 10年时共发生1477例MACE。
  • 校正临床风险后,冠心病PRS与MACE显著相关(每增加1个标准差HR 1.69,95%CI 1.60-1.79)。
  • PCE风险<7.5%但冠心病PRS处于最高五分位者较最低五分位者MACE风险显著升高(HR 10.69,95%CI 5.07-22.55)。
  • 将PRS加入临床风险评分显著改善风险预测,尤其在低临床风险者中。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The recent availability of cardiovascular risk-reducing type 2 diabetes (T2D) therapies makes it imperative to optimally identify individuals who could derive benefit. Current clinical risk prediction may misclassify individuals as low risk and could be improved. Our aim was to determine the incremental prognostic value of a coronary heart disease (CHD) genome-wide polygenic risk score (PRS) to a clinical risk score in prediction of major adverse cardiovascular events (MACE) in patients with T2D. RESEARCH DESIGN AND METHODS: We evaluated 10,556 individuals with T2D aged 40-79 years without a prior cardiovascular hospitalization. We calculated 10-year clinical cardiovascular risk at the date of recruitment using the Pooled Cohort Equation (PCE Risk) and constructed a CHD PRS. The primary outcome was time to first MACE incidence, and we assessed the additional incremental predictive value of the CHD PRS to the PCE risk. RESULTS: At 10 years, there were 1,477 MACE. After adjustment for clinical risk, the CHD PRS was significantly associated with MACE (hazard ratio [HR] 1.69 per SD increase, 95% CI 1.60-1.79). Individuals with PCE Risk <7.5% but in the top quintile of CHD PRS had a significantly increased likelihood of MACE (HR 10.69, 95% CI 5.07-22.55) compared with those in the lowest. The addition of the PRS to the clinical risk score led to significant improvements in risk prediction, particularly in those at low clinical risk. CONCLUSIONS: The addition of a CHD PRS to clinical assessment improved MACE prediction in T2D individuals without prior cardiovascular disease, particularly in those at low clinical risk.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Mordi IR, Li I, George G, et al. Incremental Prognostic Value of a Coronary Heart Disease Polygenic Risk Score in Type 2 Diabetes. Diabetes Care. 2024. PMID: 39413366. doi:10.2337/dc24-1489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。